These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1305474)

  • 21. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use.
    Kahn KL; Schneider EC; Malin JL; Adams JL; Epstein AM
    Med Care; 2007 May; 45(5):431-9. PubMed ID: 17446829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tamoxifen for the prevention of breast cancer: no.
    DeGregorio MW; Maenpaa JU; Wiebe VJ
    Important Adv Oncol; 1995; ():175-85. PubMed ID: 7672804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen and breast cancer--from palliation to prevention.
    Rich SE
    Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.
    Fink AK; Gurwitz J; Rakowski W; Guadagnoli E; Silliman RA
    J Clin Oncol; 2004 Aug; 22(16):3309-15. PubMed ID: 15310774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recruiting high risk women into a breast cancer health promotion trial.
    Lerman C; Rimer BK; Daly M; Lustbader E; Sands C; Balshem A; Masny A; Engstrom P
    Cancer Epidemiol Biomarkers Prev; 1994; 3(3):271-6. PubMed ID: 8019378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Is breast cancer prevention by tamoxifen possible?].
    Namer M; Serin D; Ferrero JM
    Bull Cancer; 1995 Jul; 82 Suppl 3():155s-167s. PubMed ID: 7492828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview.
    Keyzer JF; Melnikow J; Kuppermann M; Birch S; Kuenneth C; Nuovo J; Azari R; Oto-Kent D; Rooney M
    Ethn Dis; 2005; 15(3):395-406. PubMed ID: 16108298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease.
    Veit CT
    Med Decis Making; 2004; 24(4):330-50. PubMed ID: 15271272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
    Cykert S; Phifer N; Hansen C
    Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved screening for breast cancer associated with a telephone-based risk assessment.
    Kadison P; Pelletier EM; Mounib EL; Oppedisano P; Poteat HT
    Prev Med; 1998; 27(3):493-501. PubMed ID: 9612841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonoperative treatments for sciatica: a pilot study for a randomized clinical trial.
    Bronfort G; Evans RL; Anderson AV; Schellhas KP; Garvey TA; Marks RA; Bittell S
    J Manipulative Physiol Ther; 2000 Oct; 23(8):536-44. PubMed ID: 11050610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
    Taylor R; Taguchi K
    Ann Fam Med; 2005; 3(3):242-7. PubMed ID: 15928228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women's interest in chemoprevention for breast cancer.
    Bastian LA; Lipkus IM; Kuchibhatla MN; Weng HH; Halabi S; Ryan PD; Skinner CS; Rimer BK
    Arch Intern Med; 2001 Jul; 161(13):1639-44. PubMed ID: 11434796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitudes of pregnant women towards participation in perinatal epidemiological research.
    Nechuta S; Mudd LM; Biery L; Elliott MR; Lepkowski JM; Paneth N;
    Paediatr Perinat Epidemiol; 2009 Sep; 23(5):424-30. PubMed ID: 19689493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perceived benefits of and barriers to participation in a phase I/II colon cancer chemoprevention trial.
    Hudmon KS; Love RR; Chamberlain RM
    J Cancer Educ; 1999; 14(2):83-7. PubMed ID: 10397482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.
    Powles TJ; Hardy JR; Ashley SE; Farrington GM; Cosgrove D; Davey JB; Dowsett M; McKinna JA; Nash AG; Sinnett HD
    Br J Cancer; 1989 Jul; 60(1):126-31. PubMed ID: 2679843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment.
    Yeomans-Kinney A; Vernon SW; Frankowski RF; Weber DM; Bitsura JM; Vogel VG
    Cancer; 1995 Jul; 76(1):46-56. PubMed ID: 8630876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.